The efficacy of pantoprazole
magnesium was compared with that of esomeprazole over 4 and 8 weeks’ treatment in patients with erosive gastroesophageal reflux disease (GERD). Methods: In this multicentre (14 Brazilian sites), phase III, double-blind study, patients with erosive GERD (Los Angeles grades A–D) were randomised to pantoprazole magnesium (n = 290) or esomeprazole (n = 288), both administered at 40 mg once daily for 8 weeks. Severity of esophagitis (at endoscopy) and GERD-related symptoms (using ReQuest™-GI) were assessed at baseline and 4 and 8 weeks, and complete remission (a ReQuest™-GI score below 1.73 KPT330 plus endoscopically confirmed healing) was compared between treatments (significance p < 0.05). Results: Complete remission with pantoprazole magnesium was non-inferior to that with esomeprazole at 4 and 8 weeks (table). Mucosal healing was similar for the two treatments. However, symptom relief with pantoprazole magnesium was significantly greater at 8 weeks (p = 0.0370) than that with esomeprazole. Both PPIs had similarly low rates of adverse events. Conclusion: Pantoprazole magnesium 40 mg was as effective as esomeprazole 40 mg for complete remission and mucosal healing, but provided greater symptom relief at 8 weeks, suggesting an
extended period of treatment effect. Key Word(s): 1. GERD; 2. Symptom relief; 3. Pantoprazole; 4. Esomeprazole; Complete remission, endotcopically confirmed healing and symptom relief rates after 4 and 8 weeks (intent-to-trcat population) Assessment 4 weeks, n (%) 8 weeks, n(%) Pantoprazole magnesium Esomeprazole PLX4720 Pantoprazole magnesium MCE Esomeprazole *P = 0.0370 versus esomeprazole. Presenting Author: RAPAT PITTAYANON Additional Authors: RATHA-KORN VILAICHONE, TANISA PATCHARATRAKUL, CHINNAVAT SUTTHIVANA, WANIT PIYANIRUN, MONTIRA MANEERATANAPORN, SOMCHAI LEELAKUSOLVONG,
UDOM KACHINTORN, SUTEP GONLACHANVIT, VAROCHA MAHACHAI Corresponding Author: RAPAT PITTAYANON Affiliations: Chulalongkorn University; Thammasart University; Bhumipol Adulyadej Hospital; Pramongkulklao Hospital; Siriraj Hospital, Mahidol University Objective: Introduction: The awareness of gastroesophageal reflux disease (GERD) has led to an increased prevalence of GERD across the Asian region. It has a significant impact on quality of life and health care expenditure. Proton pump inhibitor (PPI) is commonly used to relief the symptoms. The aim of this study was to understand the patient perception on GERD, its impact on quality of life and the pattern of PPI use in GERD patients in Thailand. Methods: Methods: The physician-diagnosed GERD patients recruited from hospitals throughout Thailand participated in the 20 minute face-to-face interviews after signing informed consent. Results: Results: A total of 400 patients from 39 hospitals were enrolled.